聚乙二醇化重组人凝血因子Ⅷ在重型先天性血友病A经治患者中的免疫原性特征
本文综合分析6项临床试验中360例重型先天性血友病A经治患者的免疫原性数据。1例出现短暂FVIII抑制物(0.6 Bethesda单位/mL),未伴严重不良事件;54例存在或产生结合抗体,多为一过性,与不良事件或自发性出血无因果关联。
要点
- 360例经治患者中1例出现短暂FVIII抑制物,滴度0.6 Bethesda单位/mL,未伴严重不良事件。
- 54例患者存在或产生结合FVIII、PEG-FVIII或PEG的抗体,多为一过性。
- 结合抗体与不良事件或自发性出血无因果关联。
核心结论
- 聚乙二醇化重组人凝血因子Ⅷ未显示非预期的免疫原性特征。
研究设计与样本
- 基于6项临床试验的免疫原性数据综合分析,共纳入360例重型先天性血友病A经治患者。
主要发现
- 360例中1例出现短暂FVIII抑制物,滴度0.6 Bethesda单位/mL,未伴严重不良事件。
- 抑制物存在时未检测到结合FVIII、PEG-FVIII或PEG的抗体。
- 360例中54例在入组时即存在结合抗体或暴露后产生结合抗体,多为一过性。
- 结合抗体与不良事件或自发性出血无因果关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rurioctocog alfa pegol is an extended-half-life full-length recombinant factor VIII (FVIII) bound to 20-kDa polyethylene glycol (PEG) that has been shown to be well tolerated and efficacious in the treatment and prevention of bleeding events in previously treated patients with severe hemophilia A. Here, we present a comprehensive analysis of immunogenicity data collected during 6 clinical studies of rurioctocog alfa pegol, including a total of 360 unique previously treated patients with severe hemophilia A. The analysis included treatment-emerging FVIII-neutralizing antibodies (FVIII inhibitors); preexisting and treatment-emerging antibodies binding to FVIII, PEG-FVIII, or PEG; and treatment-emerging antibodies binding to Chinese hamster ovary host cell proteins. Moreover, the potential association between the presence of these binding antibodies and adverse events (AEs) observed in patients was investigated, and the potential impact of these antibodies on the incremental recovery of rurioctocog alfa pegol in patients was analyzed. Overall, the data indicate that rurioctocog alfa pegol is not associated with any unexpected immunogenicity characteristics. Of 360 patients, 1 patient developed a transient FVIII inhibitor with a titer of 0.6 Bethesda units per mL, which was not associated with any serious AEs. Antibodies binding to FVIII, PEG-FVIII, or PEG were not detected at the time when the inhibitor was present. Moreover, 54 of 360 patients either entered the clinical studies with preexisting binding antibodies or developed these antibodies after exposure to rurioctocog alfa pegol. These antibodies were transient in most patients and did not show any causal relationship to either AEs or spontaneous bleeding episodes.
引用
- Horling FM, Reipert BM, Allacher P, et al. Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A. Blood Adv. 2024. PMID: 38564770. doi:10.1182/bloodadvances.2023011780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。